Abstract
Aim: Type 2 cardiorenal syndrome (CRS) is characterised by chronic heart failure causing progressive chronic kidney disease. Serum complement activation in chronic heart failure was found in previously studies. The present study aims to investigate the effects of low-dose simvastatin on cardiac and renal function in patients with type 2 CRS, and to explore the underlying mechanisms involved in the complement system.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
